Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2023 · 10-Q
Revenue$26.37M$26.37M−47.4% vs Q2 2022 Net Income$2.29M$2.29MN/M vs Q2 2022 EPS Diluted$0.13$0.13N/M vs Q2 2022 Operating Income-$1,983,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$285,000N/M Margins · derivedOperating margin-7.5%−24.8 pt vs Q2 2022
Net margin8.7%+10.5 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end